9 Papers
6 Citations
Jun Lan is an academic researcher from Cardiovascular Institute of the South. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
A novel damage mechanism: Contribution of the interaction between necroptosis and ROS to high glucose-induced injury and inflammation in H9c2 cardiac cells
TL;DR: A novel damage mechanism involving the positive interaction between necroptosis and ROS attributing to HG-induced injury and inflammation in H9c2 cardiac cells is demonstrated.
The Opening of ATP-Sensitive K+ Channels Protects H9c2 Cardiac Cells Against the High Glucose-Induced Injury and Inflammation by Inhibiting the ROS-TLR4-Necroptosis Pathway.
Weijie Liang,Meiji Chen,Dongdan Zheng,Jianhao Li,Mingcai Song,Wenzhu Zhang,Jianqiang Feng,Jun Lan +7 more
TL;DR: KATP channel opening protects H9c2 cells against HG-induced injury and inflammation by inhibiting ROS-TLR4-necroptosis pathway, which mediate hyperglycemia-induced cardiac injury.
Angiotensin-(1-7) protects cardiomyocytes against high glucose-induced injuries through inhibiting reactive oxygen species-activated leptin-p38 mitogen-activated protein kinase/extracellular signal-regulated protein kinase 1/2 pathways, but not the leptin-c-Jun N-terminal kinase pathway in vitro.
Yiyan Lei,Qing Xu,Bo Zeng,Wei Zhang,Yulan Zhen,Yuansheng Zhai,Fei Cheng,Weiyi Mei,Dongdan Zheng,Jianqiang Feng,Jun Lan,Jingfu Chen +11 more
TL;DR: The mechanism of how Ang‐(1–7) can protect against HG‐stimulated injuries in H9c2 cells is shown.
26
MiR-203-3p inhibits the oxidative stress, inflammatory responses and apoptosis of mice podocytes induced by high glucose through regulating Sema3A expression
TL;DR: In this paper, the expression levels of miR-203-3p, Semaphorin 3A (Sema3A) and inflammatory cytokines were detected by quantitative real-time polymerase chain reaction.
Omalizumab for STAT3 Hyper-IgE Syndromes in Adulthood: A Case Report and Literature Review
Jun Lan,Yi Zhang,Min Song,Shan Cai,Hong Luo,Ruoyun Ouyang,Pan Yang,Xiaoliu Shi,Yingjiao Long,Yan Cheng +9 more
TL;DR: Omalizumab treatment proved beneficial in the case of HIES, especially with chronic airway disease, for which therapeutic options are limited, however, larger-scale prospective studies and long-term follow-up are required to establish the efficacy and safety of this therapeutic intervention.